Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

doi:10.1007/s12020-026-04672-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.

Endocrine - 23 Jun 2026

Colombo Elena, Ortolan Elisa, Cavalieri Stefano, Tamborini Elena, Perrone Federica, Capone Iolanda, Agnelli Luca, Paolini Biagio, Milione Massimo, Calareso Giuseppina, Salvetti Monica, Platini Francesca, Bergamini Cristiana, Alfieri Salvatore, Resteghini Carlo, Ottini Arianna, Caspani Francesca, Nuzzolese Imperia, Bottiglieri Achille, Massa Giacomo, Filippini Daria Maria, Pruneri Giancarlo, Licitra Lisa, Daidone Maria Grazia, Locati Laura Deborah

Abstract excerpt

BACKGROUND: Relapsed/metastatic anaplastic thyroid carcinoma (R/M ATC) is associated with poor prognosis. Approximately 40% of ATCs harbor the BRAFV600E mutation, for which targeted therapy is available. However, the clinical characteristics of BRAFV600E-mutant versus wild-type ATC and the role of liquid biopsy (LB) for molecular assessment and monitoring remain incompletely defined. METHODS: Consecutive patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liquid Biopsy

Share to Oximes

Share to Proto-Oncogene Proteins B-raf

Share to Pyrimidinones

Share to Tertiary Care Centers

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 42334691
DOI: 10.1007/s12020-026-04672-x
PMCID: PMC13291066

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center.PMID 42334691Read ↗

Ultrarapid BRAF mutation detection on supernatant cell-free DNA obtained by FNA: An accurate and expedient method for BRAF assessment in aggressive thyroid carcinomas.Semantic proximity Read ↗

CirculatingBRAFV600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid CarcinomaSemantic proximity Read ↗

Mutation based approaches to the treatment of anaplastic thyroid cancer.Semantic proximity Read ↗

Genomic landscape characterization and comparative analysis of tissue and liquid-based next-generation sequencing in anaplastic thyroid carcinoma in TaiwanSemantic proximity Read ↗

Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Tumor-informed liquid biopsy for monitoring thyroid cancer: a proof-of-concept study.Semantic proximity Read ↗

Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Anaplastic thyroid carcinoma in Argentina: real-world diagnostic lags and treatment barriersSemantic proximity Read ↗

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.Semantic proximity Read ↗

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.Semantic proximity Read ↗

Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.